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FINANCIAL AND NON-FINANCIAL CONFLICTS OF INTERESTS 
IN PSYCHIATRY
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Abstract: A conflict of interests occurs when a doctor is unduly influenced by a secondary interest (i.e., a personal incentive) in his acts 
concerning one of the primary interests to which he is professionally committed (the welfare of patients, the progress of science or the 
education of students or residents). One specific variety of conflicts of interests has monopolized the attention of the scientific and lay press: 
the financial conflicts of interests arising from the relationships between doctors and drug companies. A large literature has described the 
many, sometimes subtle, ways by which a psychiatrist can be influenced in his prescribing habits or research activities by his relationships 
with the industry. Some empirical evidence is now available in this area. On the other hand, it has been pointed out that the current 
debate on this issue is sometimes “affectively charged”, or fails to take into account that the interests of patients, families and mental health 
professionals and those of the industry may be often convergent. Other types of conflicts of interests are beginning now to be discussed. 
There is evidence that the allegiance of a researcher to a given school of thought may influence the results of studies comparing different 
psychotherapeutic techniques, thus colliding with the primary interest represented by the progress of science. Political commitment is also 
emerging as a source of conflicts of interests. Financial and non-financial conflicts of interests are widespread in psychiatric practice and 
research. They cannot be eradicated, but must be managed more effectively than is currently the case. 
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CONFLICTOS DE INTERESES FINANCIEROS Y NO FINANCIEROS EN PSIQUIATRÍA 
Resumen: Se produce un conflicto de intereses cuando un médico se siente indebidamente influenciado por un interés secundario (i.e., un 
incentivo personal) en relación con sus deberes primarios con los cuales está comprometido profesionalmente (el bienestar de los pacientes, 
el progreso de la ciencia o la educación de los estudiantes o residentes). Una variedad específica de conflictos de intereses ha monopolizado 
la atención de la prensa científica así como de la no especializada: los conflictos de intereses financieros que surgen de la relación entre 
médicos y compañías farmacéuticas. Una extensa literatura ha descrito las variadas maneras, a veces sutiles,  por medio de las cuales un 
psiquiatra puede ser influenciado por sus relaciones con la industria al aconsejar hábitos, o en sus actividades de investigación. Hoy en día 
se puede obtener algo de evidencia empírica en esta área. Por otra parte, se ha señalado que, a veces, el actual debate sobre esta materia se 
ve “cargado afectivamente” o falla en considerar que los intereses de los pacientes, de sus familias y de los profesionales de la salud mental y 
los de la industria podrían converger. Actualmente, se está empezando a  discutir acerca de otros conflictos de intereses. Existe evidencia de 
que la cercanía de un investigador a alguna línea de pensamiento puede influenciar los resultados de estudios al comparar diferentes técnicas 
psicoterapéuticas, chocando, por tanto, con el interés primario representado por el progreso de la ciencia. El compromiso político también 
está emergiendo como fuente de conflictos de intereses. Conflictos de intereses financieros y no financieros están muy esparcidos en la práctica 
y la investigación psiquiátricas. No pueden ser erradicados, pero deben ser tratados con mayor eficacia de la que se observa hoy en día.
Palabras clave: conflictos de intereses, industria farmacéutica, sesgo de la publicación, desvelar, efecto de lealtad, compromiso político
CONFLITOS DE INTERESSES FINANCEIROS E NÃO FINANCEIROS EM PSIQUIATRIA
Resumo: Ocorre conflito de interesses quando um médico se sente indevidamente influenciado por um interesse secundário (i.e., um incentivo 
pessoal) em relação aos seus deveres primários, com os quais está comprometido profissionalmente (o bem-estar dos pacientes, o progresso 
da ciência, a educação dos estudantes ou residentes). Uma variedade específica de conflitos de interesses tem monopolizado a atenção da 
literatura científica, assim como da não especializada: os conflitos de interesses financeiros que surgem da relação entre médicos e companhias 
farmacêuticas. Uma extensa literatura tem descrito as variadas maneiras, às vezes sutis, nas quais um psiquiatra pode ser influenciado devido 
às suas relações com a indústria ao aconselhar hábitos, ou em suas atividades de pesquisa. Hoje em dia, pode-se obter alguma evidência 
empírica nesta área. Por outra parte, tem-se assinalado que, às vezes, o atual debate sobre esta matéria se vê “carregado afetivamente” ou 
falha ao considerar que os interesses dos pacientes, de suas famílias, dos profissionais da saúde mental e os da indústria poderiam convergir. 
Atualmente, está se iniciando a discussão sobre outros conflitos de interesses. Existe evidência de que a proximidade de um pesquisador 
com alguma linha de pensamento pode influenciar os resultados de estudos ao comparar diferentes técnicas psicoterapêuticas, conflitando, 
portanto, com o interesse primário representado pelo progresso da ciência. O compromisso político também está emergindo como fonte 
de conflitos de interesses. Conflitos de interesses financeiros e não financeiros estão muito difundidos na prática e na pesquisa psiquiátricas. 
Não podem ser erradicados, porém devem ser tratados com maior eficácia em relação ao que se observa hoje em dia.
Palavras-chave: conflitos de interesses, indústria farmacêutica, obliquidade da publicação, cuidar, efeito de lealdade, compromisso 
político
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A conflict of interests occurs when a doctor is unduly 
influenced by a secondary interest (i.e., by a personal 
incentive) in his acts concerning one of the primary in-
terests to which he is professionally committed(1-3).
The primary interests to which a doctor is professionally 
committed are: first of all, the welfare of his patients; 
then, if he is a researcher, the progress of science; and, 
if he is a scholar, the education of his students, residents 
or colleagues(1-3). 
A conflict may also arise between two of these primary 
interests. For instance, between the welfare of an indi-
vidual patient and the progress of science. This conflict 
has been covered in the literature, and usually referred 
to as the “clinician-scientist dilemma”. The expression 
“conflict of interests” is not used in this case. Further-
more, a doctor may have other professional roles in 
addition to those of clinician, scientist and scholar. For 
instance, he may act as a consultant to the judiciary 
system or to the government. This may be a source of 
conflicts. This issue has been covered in the literature 
concerning the practice of forensic psychiatry, where 
there is often a potential conflict between the welfare 
of individual patients and the mandate the psychiatrist 
receives from the court(4). This conflict, however, is 
rarely referred to as a conflict of interests. The expres-
sion “dual commitment” or “dual loyalty” conflict is 
more frequently used. 
The expression “conflict of interests” is commonly 
used, instead, when a conflict arises between one of the 
above-mentioned primary interests to which a doctor 
is professionally committed and one of several possible 
secondary interests (i.e. personal incentives). These 
secondary interests include: a) the motivation to obtain 
a financial gain for oneself or an institution (such as a 
hospital or a university department); b) the motivation 
to obtain personal recognition, career advancement 
or visibility in the media (the so-called academic cur-
rency); c) the motivation to favour a relative, a friend 
or a colleague; d) the allegiance to a school of thought, 
a socio-political position or a religious belief(1-3). 
Having a potential conflict of interests, i.e., one which 
is seen as possibility, is different from having an actual 
conflict of interests, i.e., one documented as a fact. A 
common misunderstanding is that having a potential 
conflict of interest means that the individual is neces-
sarily doing something wrong or unethical. On the 
contrary, judging that a potential conflict of interests 
exists in a given situation means that the situation is 
such that any well-intentioned person might be subtly 
influenced(5).
Also, a potential conflict of interests may be more or less 
substantial. Being a regular consultant or in the board 
of directors of a drug company is not the same thing as 
eating a pizza at an industry-sponsored lunch(6).
It is also important to clarify that a conflict of interests 
may or not be perceived as such by the involved person. 
Actually, it is common for people to believe that they 
are invulnerable to influences to which they believe 
others are susceptible(7). 
Financial conflicts of interests arising from 
relationships to drug companies
Of the universe of conflicts of interests which may oc-
cur in medical (and psychiatric) research and practice, 
one specific variety has monopolized the attention 
of the scientific and lay press: the financial conflicts 
of interests arising from the relationships between 
physicians and drug companies. Much has been said 
and much has been written on this issue. Let us focus 
on the points which are currently supported by some 
empirical evidence.
It is to some extent documented that accepting funds 
for travel and accommodation on the occasion of 
sponsored symposia is associated with an increased 
prescription of the sponsor’s medications, and that 
physicians who use to request the addition of drugs 
to their hospital formulary are more likely to have ac-
cepted money from drug companies(8).
It is also documented that studies sponsored by the 
industry are more likely to report outcomes favourable 
to the sponsor’s product(9). A systematic review(10) 
found that in 90% of head-to-head comparison stud-
ies of second-generation antipsychotics the reported 
overall outcome was in favour of the sponsor’s drug. 
Another study(11) reported that authors’ conflict of 
interests was significantly associated with positive 
trial outcomes in industry-supported clinical trials in 
psychiatry. 
Since almost all trials of new medications in the psy-
chiatric field are now funded by a drug company, the 
suspicion is warranted that recent research evidence 
in the field of psychopharmacotherapy is to some 
extent biased. 
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The sources of bias in the design, conduct and data 
analysis include(12): a) using a dose of the comparison 
drug which is outside its standard clinical range; b) 
altering the usual dosing schedule of that comparison 
drug; c) using self-serving assessment instruments; d) 
using misleading statistical analyses; e) picking favour-
able endpoints and outcome measures a posteriori. 
The sources of bias in the report of the results of trials 
include(12): a) selectively emphasizing findings which 
are favourable to the sponsored drug; b) masking 
unfavourable side effects of that drug; c) repeatedly 
publishing the same data in papers with a different 
first author (so that even meta-analyses and systematic 
reviews may be misled); d) publishing data in sponsored 
supplements where papers are not peer-reviewed; e) 
withholding unfavourable results.
In addition to this, it has been claimed that eminent 
researchers with significant financial conflicts of in-
terests may exercise their impact on the field also in 
their role of referees or editors of scientific journals, 
thus creating what have been called “special interest 
groups”(13).
The same experts are also the most likely to contribute 
to the production of clinical guidelines. In fact, a fur-
ther well-documented evidence is that most authors of 
clinical practice guidelines have financial relationships 
with companies whose drugs are considered in those 
guidelines. A study showed that 59% of contributors 
to clinical guidelines had received financial support 
from the industry. Only 7% of them thought that their 
relationship with drug companies had influenced their 
own recommendations, whereas the percentage of those 
who thought that their co-authors’ recommendations 
had been influenced was three times higher(14). 
A further point which is now to some extent docu-
mented is that industry-sponsored CME activities 
are often biased in favour of the sponsor’s products, 
and that physicians attending those activities tend to 
prescribe those products more often than competing 
drugs(15). In several countries, there are now so-called 
medical education and communication agencies, paid 
by drug companies, which put together the programme 
of sponsored CME events, select and pay the speak-
ers, and sometimes prepare the speakers’ slides(16). 
These agencies are very clear in explaining the purpose 
of their business to drug companies. These are some 
quotes from their advertisements: “Medical education 
is a powerful tool that can deliver your message to 
key audiences and get those audiences to take action 
that benefits your product”; “Putting the science of 
medicine to work for you. Preparing and building the 
market through professional education”(16). 
The main antidote to this situation that our profes-
sion has been able to develop is disclosure (i.e., the 
disclosure of potential financial conflicts of interests by 
researchers authoring a scientific paper, contributing to 
the production of clinical guidelines, or presenting at a 
scientific meeting or a CME course). The idea is that, 
since eradicating or even limiting financial conflicts of 
interests is unfeasible, at least the readership of scientific 
journals and the audience of scientific meetings should 
be aware of their existence and of the possibility that the 
evidence presented be consequently biased. However, 
this antidote has not been very effective up to now. In 
fact, while self-reports reveal that more than 33% of 
senior journal authors have financial ties to funders of 
research, the rate of self-disclosure in journals has been 
reported to be less than 2%(17). 
The International Committee of Medical Journal Edi-
tors has recently produced “Uniform requirements for 
manuscripts submitted to biomedical journals”, stating 
that “when authors submit a manuscript, whether an 
article or a letter, they are responsible for disclosing 
all financial and personal relationships that might bias 
their work”(18).
The crucial point, however, is what happens if some-
body refuses or fails to disclose a relationship with 
industry. The consequences of this refusal or failure 
should be substantial enough to ensure the effective-
ness of the policy(19). Indeed, some professional as-
sociations have issued statements according to which 
failure to disclose a financial conflict of interests may 
constitute grounds for disciplinary action(20). How-
ever, professional associations are usually too remote to 
be effective, and it should be the responsibility of local 
institutions to establish a peer review committee which 
is really functioning and deals with these issues(19). On 
the other hand, concerns have been also raised about 
common conflicts of interests of members of institu-
tional review boards, who may be inappropriately critic 
of other colleagues due to jealousy over their achieve-
ments or different school orientations(21). 
Concerning the issue of publication bias, a possible 
antidote which has been frequently proposed is the 
creation of a registry in which all new trials are re-
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corded when they start. This idea has been recently 
implemented by the World Health Organization, 
which has launched an International Clinical Trials 
Registry Platform, urging research institutions and 
companies to register all medical studies that test 
treatments on patients or healthy volunteers(22). The 
issue of publication policies has been also addressed in 
a set of good publication guidelines for pharmaceuti-
cal industry, produced by a working group including 
several companies, although a final disclaimer specifies 
that the guidelines may not necessarily represent the 
policies of those companies(23).
Has the issue of financial conflicts of interests 
been overemphasized in psychiatry?
Four main arguments have been put forward by those 
who believe that the issue of financial conflicts of inter-
ests arising from the relationships between psychiatrists 
and drug companies has been overemphasized in the 
field of psychiatry.
The first argument is that the current debate on fi-
nancial conflicts of interests in the psychiatric field is 
sometimes biased by ideological prejudice: “The debate 
on this issue may have become so vitriolic in psychiatry 
because it taps into a more profound disagreement 
about the role of drugs in psychiatry”(24). A more 
general critique of capitalism may also be involved: 
“Is the making of money on the back of drug develop-
ment and sales somehow immoral?”(24). Moreover, 
an oppositional attitude towards drug companies may 
carry professional benefits, including a priority when 
public money is distributed for research(25). This 
argument is certainly an interesting one. However, it 
should not be brought so far as to deny the impact of 
financial conflicts of interests on the psychiatric field, 
especially since this impact is now well documented 
by research evidence. 
The second argument is that the current focus on 
financial conflicts of interests arising from the rela-
tionships between psychiatrists and drug companies 
sometimes fails to take into account the fact that the 
pharmaceutical industry is today virtually the only 
source of development of new medications in our 
field, and that we, our patients and their families do 
need new, more effective, better tolerated and more 
targeted medications. To a large extent, therefore, our 
interests, those of patients and their families and those 
of the industry may be regarded as convergent(26-28). 
However, this is not necessarily true, if the new drugs 
which are promoted are more expensive and do not 
really bring significant advantages with respect to the 
old ones. Furthermore, the fact that we are necessarily 
partners does not mean that this partnership should 
not have clear rules, better if agreed upon by both 
parties involved. 
The third argument is that drug companies are today, in 
many countries, the only accessible source of financial 
support for drug trials, the organization of large scien-
tific meetings and CME events, so that it is practically 
unavoidable for a professional who wants to implement 
one of those activities to look for the support of the in-
dustry. This is most probably true. However, again, the 
fact that a partnership is unavoidable does not imply 
that such a partnership should not have rules.
The fourth argument is that the relationship with drug 
companies is not the only source of financial conflicts 
of interests for physicians and researchers, although 
it is by large the most visible. This is certainly a good 
point. There are indeed financial conflicts of interests 
in psychiatric practice and research which do not 
involve the pharmaceutical industry. For instance, 
public health sponsors usually have an interest to avoid 
spending money on the most expensive drugs(25). 
This may affect the conduct and the outcome of the 
studies they fund (e.g., comparisons between old- and 
new-generation drugs), especially if the report of re-
sults in line with the public sponsor’s interest involves 
a better chance for researchers to be funded again by 
that sponsor.
Another almost unexplored issue is that of financial 
conflicts of interests related to the practice of managed 
care(29). Many physicians are currently pressured by 
their administrations to be more “productive” (i.e., to 
see more patients during working hours) and to use 
the least expensive interventions. This increased pro-
ductivity and use of the cheapest treatments may not 
be in the best patients’ interest. If a financial incentive 
is involved, which is often the case, a financial conflict 
of interests may be generated. 
Non-financial conflicts of interests in 
psychiatry
Financial conflicts of interests have attracted a lot of 
interest in the past few decades. However, they are 
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certainly not the only conflicts of interests affecting 
research and practice in medicine, and particularly in 
psychiatry. 
An example of non-financial conflict of interests af-
fecting psychiatric research is given by the possible 
conflict between the secondary interest represented by 
the researcher’s allegiance to a given school of thought 
and the primary interest represented by the progress 
of science(3). 
The impact of this “allegiance effect” on the outcome of 
psychotherapy research has been repeatedly described. 
A systematic review(30) found that the combination 
of three measures of researcher’s allegiance accounted 
for 69% of the effect size of treatment outcome in 
studies comparing three psychotherapeutic tech-
niques. Interestingly, some mechanisms by which the 
researcher’s allegiance may operate are very similar to 
those explaining the impact of financial conflicts of 
interests on the outcome of drug trials: the selection 
of a less effective intervention to compare with the 
researcher’s favoured treatment; the unskilful use of the 
comparison treatment; a focus on data favouring the 
preferred treatment in study reports; and the failure to 
publish negative data. 
The impact of this allegiance effect (along with the fact 
that the proponents of some psychotherapies may for 
various reasons be less interested in the scientific valida-
tion of their techniques) may bias the research evidence 
concerning the relative efficacy of the various psycho-
therapies, exactly like the impact of financial conflicts 
of interests may bias the research evidence concerning 
the relative efficacy of the various psychotropic drugs. 
Not surprisingly, it has been argued that “the balance of 
investigator allegiance across the schizophrenia litera-
ture is against psychodynamic or supportive methods 
and in favour of CBT approaches”(31). 
An example of non-financial conflict of interests af-
fecting psychiatric practice is given by the possible 
conflict between the secondary interest represented by 
a psychiatrist’s political commitment and the primary 
interest represented by patients’ welfare(3).
In my country, a minister of education stated some 
years ago that a psychiatrist should always be a political 
activist, and, indeed, being a political activist may be 
very useful to a psychiatrist in fulfilling his professional 
duties. However, it is a fact that some political orien-
tations are often associated with a strong prejudicial 
attitude against the use of medications in psychiatry 
and the hospitalization of psychiatric patients. This 
prejudicial attitude may sometimes amount to fanati-
cism (“those who prescribe psychotropic drugs are like 
pushers”; “psychiatry does not need any beds”). 
Of course, everybody is free to hold and profess even 
extreme ideas, and one could argue that these views 
may sometimes represent a stimulus to the field. How-
ever, if a psychiatrist holding such ideas (or, even worse, 
a psychiatrist wishing to please a head physician or a 
manager holding such ideas) denies pharmacological 
treatment and/or hospitalization to a severely depressed 
patient, who then commits suicide, isn’t this a tragic 
instance of conflict between the secondary interest 
represented by the psychiatrist’s political commitment 
and the primary interest represented by the patient’s 
welfare?(3). 
A prejudicial attitude against the use of medications 
in psychiatry may more often manifest itself as the 
stubborn refusal to learn to use those medications ad-
equately, and to even consider reading drug treatment 
guidelines, because this would mean to acknowledge 
the essential therapeutic role of something which is 
instead regarded as an only marginal ingredient of care. 
The consequence of this attitude is that medications are 
indeed used, but in an irrational and chaotic way, again 
with a significant detriment to patients’ welfare(3). 
As I mentioned above, it has been rightly pointed 
out that there are now in our field “special interest 
groups”, consisting of prominent leaders with sig-
nificant financial conflicts of interests (arising from 
their relationships to drug companies) who exercise a 
powerful impact on the field in their various capaci-
ties (e.g., as editors or referees of scientific journals, or 
contributors to treatment guidelines)(13). One could 
argue, however, that similar “special interest groups” 
consisting of prominent leaders with significant ideo-
logical conflicts of interests may also exist. They may 
exercise an equally powerful impact on the field acting, 
for instance, as contributors to mental health policy 
guidelines or consultants to governments. Further-
more, another emerging circle is that of “two-sided” 
experts, eloquently advocating opposite positions (for 
instance, in favour or against the use of new-generation 
medications) depending on the context in which they 
speak (e.g., a sponsored symposium vs. a meeting of a 
governmental task force)(3).
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Conclusion
Conflicts of interests are widespread in medical, 
and psychiatric, practice and research. Financial 
conflicts of interests, particularly those arising from 
the relationships of physicians and researchers to the 
pharmaceutical industry, have a significant impact on 
the psychiatric field, now to some extent documented 
by research. However, non-financial conflicts of in-
terests are probably both common and significant in 
psychiatric practice and research, although currently 
underemphasized and understudied. 
Conflicts of interests in psychiatric research and prac-
tice cannot be eradicated, but must be managed more 
effectively than is currently the case, and this is certainly 
an area which our professional associations should be 
more active in the future.
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